We are live on ! Find out more
DM

Deerfield Management Portfolio holdings

AUM $9.59B
1-Year Est. Return 113.36%
This Fund
S&P 500
This Quarter Est. Return
-7.49%
1 Year Est. Return
+113.36%
3 Year Est. Return
+277.48%
5 Year Est. Return
+350.78%
10 Year Est. Return
+2,290.11%
AUM
$2.45B
AUM Growth
-$331M
Cap. Flow
-$447M
Cap. Flow %
-18.22%
Top 10 Hldgs %
43.96%
Holding
111
New
16
Increased
20
Reduced
24
Closed
16

Top Buys

Rank Stock Value
1
MIRM icon
Mirum Pharmaceuticals
MIRM
+$42.3M
2
RYTM icon
Rhythm Pharmaceuticals
RYTM
+$42.2M
3
AERI
Aerie Pharmaceuticals
AERI
+$35.2M
4
SWTX
SpringWorks Therapeutics
SWTX
+$24.8M
5
CNC icon
Centene
CNC
+$20.3M

Top Sells

Rank Stock Value
1
NTRA icon
Natera
NTRA
+$27.7M
2
IMMU
Immunomedics Inc
IMMU
+$26M
3
STAA icon
STAAR Surgical
STAA
+$25.8M
4
NVRO
NEVRO CORP.
NVRO
+$25M
5
NVTA
Invitae Corporation
NVTA
+$23.4M

Sector Composition

Rank Sector Weight
1 Healthcare 79.66%
2 Miscellaneous 20.04%
3 Financials 0.3%
4 Consumer Discretionary 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
HZNP
1
DELISTED
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
$176M 7.17%
6,462,634
– –
VTRS icon
2
Viatris
VTRS
$19.5B
$151M 6.17%
7,654,065
+189,738
+3% +$3.72M
ORTX
3
DELISTED
Orchard Therapeutics plc American Depositary Shares
ORTX
$106M 4.32%
892,360
– –
QTTB icon
4
Q32 Bio
QTTB
$381M
$104M 4.25%
320,020
– –
AERI
5
DELISTED
Aerie Pharmaceuticals
AERI
$87.8M 3.58%
4,568,824
+1,535,837
+51% +$35.2M
RYTM icon
6
Rhythm Pharmaceuticals
RYTM
$7.22B
$55.9M 2.28%
2,589,291
+1,965,358
+315% +$42.2M
BKD icon
7
Brookdale Senior Living
BKD
$2.85B
$54.6M 2.23%
7,207,239
– –
XENT
8
DELISTED
Intersect ENT, Inc
XENT
$52.9M 2.16%
3,109,004
– –
XLRN
9
DELISTED
Acceleron Pharma
XLRN
$51.6M 2.1%
1,305,174
– –
MYOK
10
DELISTED
MyoKardia, Inc. Common Stock
MYOK
$51.2M 2.09%
981,430
-15,570
-2% -$828K
IMMU
11
DELISTED
Immunomedics Inc
IMMU
$42.6M 1.74%
3,214,000
-1,771,383
-36% -$26M
RARX
12
DELISTED
Ra Pharmaceuticals, Inc. Common Stock
RARX
$40.9M 1.67%
1,728,019
+15,019
+0.9% +$445K
MIRM icon
13
Mirum Pharmaceuticals
MIRM
$6.14B
$34.7M 1.41%
+3,448,912
New +$42.3M
ARGX icon
14
argenx
ARGX
$65.9B
$32M 1.31%
281,000
– –
SILK
15
DELISTED
Silk Road Medical, Inc. Common Stock
SILK
$31.9M 1.3%
979,480
+480,450
+96% +$19.1M
VCEL icon
16
Vericel Corp
VCEL
$2.07B
$31.5M 1.28%
2,081,000
+11,399
+0.6% +$199K
CHRS icon
17
Coherus Oncology
CHRS
$212M
$31.2M 1.27%
1,540,305
-137,717
-8% -$2.75M
CNC icon
18
Centene
CNC
$33.6B
$31.2M 1.27%
720,400
+417,400
+138% +$20.3M
FATE icon
19
Fate Therapeutics
FATE
$290M
$30.3M 1.24%
1,952,897
+250,000
+15% +$4.79M
ALEC icon
20
Alector
ALEC
$280M
$29.9M 1.22%
2,076,812
+329,889
+19% +$5.96M
SRPT icon
21
Sarepta Therapeutics
SRPT
$2.43B
$28.8M 1.17%
382,000
+72,975
+24% +$8.62M
SEM
22
DELISTED
Select Medical
SEM
$28.4M 1.16%
3,181,368
-611,418
-16% -$5.34M
BPMC
23
DELISTED
Blueprint Medicines
BPMC
$27.7M 1.13%
377,200
-14,054
-4% -$1.21M
DBVT
24
DBV Technologies
DBVT
$861M
$27.5M 1.12%
320,122
– –
SIEN
25
DELISTED
Sientra, Inc.
SIEN
$26.8M 1.09%
413,747
-51,484
-11% -$3.27M
1
2 3 4 5

Similar funds

OAM
Oppenheimer Asset Management New York $9.63B AUM 30.32% 1-Year Est. Return
BTI
Blue Trust Inc Alpharetta, Georgia $9.54B AUM 19.86% 1-Year Est. Return
WAM
Weiss Asset Management Boston, Massachusetts $9.54B AUM 55.06% 1-Year Est. Return
MSE
MUFG Securities EMEA London, United Kingdom $9.53B AUM 52.96% 1-Year Est. Return
VF
Vest Financial Mclean, Virginia $9.52B AUM 31.6% 1-Year Est. Return
GGHC
Gilder Gagnon Howe & Co New York $9.69B AUM 55.7% 1-Year Est. Return
A
Allianz Munich, Germany $9.48B AUM 23.58% 1-Year Est. Return
Edgewood Management
Edgewood Management Greenwich, Connecticut $9.69B AUM 6.52% 1-Year Est. Return

Deerfield Management's Q3 2019 Portfolio in Review

As of Q3 2019, Deerfield Management held 111 positions worth $2.45B, down 12% from $2.78B the previous quarter. Its ten largest holdings account for 44% of the portfolio.

Deerfield Management withdrew a net $447M in Q3 2019, closing 16 positions and reducing 24 holdings. Its most notable exit was Natera, an estimated $27.7M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 80% of assets, up from 79% a quarter earlier, followed by Miscellaneous and Financials.

Against the trend, Deerfield Management opened a new position in Mirum Pharmaceuticals worth $34.7M.

  • Deerfield Management's largest Q3 2019 buy was Mirum Pharmaceuticals: 3,448,912 shares worth $34.7M.
  • Deerfield Management added most to Rhythm Pharmaceuticals in Q3 2019, an estimated $42.2M increase.
  • Deerfield Management's biggest Q3 2019 reduction was Immunomedics Inc, cutting an estimated $26M.
  • Deerfield Management fully exited Natera in Q3 2019, selling an estimated $27.7M.
  • Deerfield Management's ten largest holdings make up 44% of its $2.45B portfolio in Q3 2019.
  • Deerfield Management opened 16 new positions and closed 16 in Q3 2019.
  • Deerfield Management's portfolio value fell 12% quarter-over-quarter to $2.45B.

Based on Deerfield Management's 13F filing for Q3 2019, filed 14 Nov 2019.